Ir al contenido principal


Mostrando entradas de mayo, 2018

Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma-Critical Appraisal

Analysis by Ines Luna
This is the link of trial :
 It is a interesting study about how a monoclonal antibody agent can improve de function, reduce exacerbation ad reduce oral glucortucoids drugs in patients with severe asthma.
Methods : 
Were randomly assigned 210 patients with oral glucocorticoid–treated asthma to receive add-on dupilumab (at a dose of 300 mg) or placebo every 2 weeks for 24 weeks. After a glucocorticoid dose-adjustment period before randomization, glucocorticoid doses were adjusted in a downward trend from week 4 to week 20 and then maintained at a stable dose for 4 weeks. The primary end point was the percentage reduction in the glucocorticoid dose at week 24. Key secondary end points were the proportion of patients at week 24 with a reduction of at least 50% in the glucocorticoid dose and the proportion of patients with a reduction to a glucocorticoid dose of less than 5 mg per day. Severe exacerbation rate…